Vaccines

Sales Performance Vaccine Development Covid-19 COVID-19 vaccines FDA Approval

GSK Reports Strong Q1 Results, Confirms Readiness for Potential US Pharma Tariffs

The company surpassed analyst expectations, reaffirmed 2025 guidance, and outlined strategies to mitigate tariff impacts while navigating mixed portfolio performance.

4 ARTICLES

11mo ago

Biden to Fund Free COVID Vaccines, Treatment for Uninsured through 2022

Vaccines

GSK Reports Strong Q1 Results, Confirms Readiness for Potential US Pharma Tariffs

GSK Raises 2024 Targets Amid Strong Cancer and HIV Treatment Sales

Pfizer and Merck Diverge in Q2 Performance Amid Revised Forecasts

Moderna Suspends Construction of Vaccine Plant in Kenya Due to Low Demand

Biden to Fund Free COVID Vaccines, Treatment for Uninsured through 2022